Lanean...

Advancements in Therapy for Bladder Cancer: Enfortumab Vedotin

The treatment paradigm for urothelial carcinoma (UC), a common genitourinary cancer, has significantly expanded in recent years. Enfortumab vedotin, a Nectin-4–targeted antibody-drug conjugate, was recently approved by the U.S. Food & Drug Administration for patients with advanced or metastatic...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Adv Pract Oncol
Egile nagusia: Hanna, Kirollos S.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Harborside Press LLC 2020
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7863123/
https://ncbi.nlm.nih.gov/pubmed/33604101
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.6004/jadpro.2020.11.4.8
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!